Article info
Interstitial lung disease
Original article
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
- Correspondence to Professor Rachel C Chambers, Centre for Inflammation and Tissue Repair, UCL Respiratory, Rayne Institute, 5 University Street, University College London, London WC1E 6JJ, UK; r.chambers{at}ucl.ac.uk
Citation
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Publication history
- Received June 15, 2015
- Revised March 14, 2016
- Accepted March 15, 2016
- First published April 21, 2016.
Online issue publication
September 01, 2022
Article Versions
- Previous version (14 July 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/